# Trade Mark Journal No.2026/032 7 August 2026

## UK00004421620 27 July 2026 (5,42,44)

RINLYGRA

Class 5
  Pharmaceuticals; pharmaceutical preparations; pharmaceutical products; insulin; insulin glargine; insulin analog; anti-diabetics; pharmaceuticals for treating diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical products for treating diabetes; pharmaceutical preparations, namely, injectable insulin; pharmaceutical preparations, namely, injectable insulin glargine; pharmaceutical preparations, namely, injectable insulin analog; pharmaceutical preparations, namely, injectable anti-diabetics; injectable pharmaceutical preparations for treating diabetes; injectable pharmaceutical products for treating diabetes; injectors sold filled with insulin; insulin injectors sold filled with insulin glargine; insulin injectors sold filled with insulin analog; injectors sold filled with pharmaceuticals for treating diabetes; injectors sold filled with anti-diabetics.
Class 42
  Providing information in the field of scientific and medical research related to pharmaceuticals; providing information in the field of scientific and medical research related to diabetes; research and development of pharmaceuticals; research and development of pharmaceuticals in the field of diabetes.
Class 44
  Providing medical information; providing health information; providing medical information in the field of diabetes; providing health information in the field of diabetes; medical and pharmaceutical consultation; pharmaceutical advice; providing information to patients in the field of administering medications; individual medical counseling services provided to patients; providing personal support services for families of patients with life threatening disorders, namely, health counseling services.

Emerge Bioscience Pte. Ltd.

Representative: Bryers Intellectual Property Ltd